Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

real-time data

- PMLiVE

Novo Nordisk’s semaglutide approved by MHRA to prevent cardiovascular event risk

Approximately 7.6 million people are living with heart and circulatory diseases in the UK

- PMLiVE

NHS figures reveal record number of people in England being diagnosed with dementia

Around a third of people living with dementia in England have not received a diagnosis

- PMLiVE

Merck’s investigational RSV monoclonal antibody clesrovimab shown to protect infants

The respiratory virus accounts for about 30,000 hospitalisations in children under five every year in the UK

- PMLiVE

GSK’s ViiV shares positive head-to-head results for two-drug HIV regimen Dovato

The phase 4 trial has been comparing Dovato against Gilead’s three-drug regimen, Biktarvy

- PMLiVE

Researchers develop AI model to identify breast cancer stages and progression

Up to 50% of ductal carcinoma in situ patients progress to a highly invasive stage of cancer

- PMLiVE

How good are you at filtering fact from fiction?

By Vicky Bramham

- PMLiVE

How patient engagement improves outcomes in chronic illness

By Chloe Patel

- PMLiVE

Generative AI, storytelling and patient inclusion: key publications trends in 2024

By Teal Brechtel and Jennifer Gillman

Amiculum

- PMLiVE

FDA approves Samsung Bioepis’ Soliris biosimilar Epysqli for rare blood disorders

Epysqli has been authorised to treat paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome

- PMLiVE

MHRA approves first generic raltegravir medicines to treat HIV in adults and children

More than 91,000 people in England were diagnosed with HIV and accessing care in 2022

- PMLiVE

Paratek announces positive late-stage results for Nuzyra in bacterial pneumonia

The condition, caused by various bacteria, affects more than 900,000 people in the US every year

- PMLiVE

Q&A with Springer Nature’s Leslie Lansman

Ethical content sharing and the benefits of the CLA Pharmaceutical Licence

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links